Khanh Toan Nguyen^1,*, Thi Huong Pham^1,2, Van Lam Ngo¹, Thi Thuy My Nguyen¹, Thi Dao Nguyen¹, Khanh Hung Truong¹, Van Nhat Nguyen¹, Van Thanh Le¹, Ba Duc Ho¹, Thi Phuong Thao Nguyen¹, Thi Ha Phuong Nguyen¹, Thi My Linh Dinh¹, Thi Hong Anh Vo¹, Thi Thuy Phan¹, Thi Hai Yen Le¹, Thi Nhung Ngo¹, Khanh Ha Nguyen¹

Oncology Research, Vol.33, No.12, pp. 4013-4028, 2025, DOI:10.32604/or.2025.069281 - 27 November 2025

Abstract Objective: Patients with stage III non-small cell lung cancer (NSCLC) present with a heterogeneous disease profile and often require multifaceted treatment strategies. This research aimed to investigate the demographic features, therapeutic patterns, and survival outcomes of such patients in Vietnam. Methods: A retrospective descriptive study was conducted on 731 patients diagnosed with stage III NSCLC American Joint Committee on Cancer (AJCC) 8th edition, at Nghe An Oncology Hospital from January 2018 to August 2024. Descriptive statistics summarized baseline and treatment characteristics. We calculated progression-free survival (PFS) and overall survival (OS) through the Kaplan–Meier approach and… More >

Xiangyu Yan^1,#, Yusheng Jin^1,#, Yan Yuan¹, Xubaihe Zhang¹, Jiayi Li¹, Ying Xu¹, Yangyang Ge², Anqing Wu^1,*

BIOCELL, Vol.49, No.10, pp. 1929-1946, 2025, DOI:10.32604/biocell.2025.066935 - 22 October 2025

Abstract Objectives: Fractionated radiotherapy represents a standardized and widely adopted treatment modality for cancer management, with approximately 40% of non-small cell lung cancer (NSCLC) patients receiving it. However, repeated irradiation may induce radioresistance in cancer cells, reducing treatment effectiveness and raising recurrence risk. The long noncoding RNA CRYBG3 (lncRNA CRYBG3), which is upregulated in lung cancer cells after X-ray irradiation, contributes to the radioresistance of NSCLC cells by promoting wild-type p53 protein degradation. This study aims to elucidate the mechanism of fractionated irradiation-induced radioresistance, in which lncRNA CRYBG3 regulates radiation-induced mitochondrial damage and reactive oxygen species… More >

Eleni Kokkotou^*, Andriani Charpidou, Nikolaos Syrigos

Oncology Research, Vol.33, No.10, pp. 2657-2672, 2025, DOI:10.32604/or.2025.066228 - 26 September 2025

Abstract Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) serve an essential role in tumor angiogenesis and have emerged as potential therapeutic targets in lung cancer. This review explores the significance of serum VEGF levels as a predictive biomarker in non-small cell lung cancer (NSCLC). The VEGF family, consisting of VEGFA, VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF), engages with specific receptors, including tyrosine kinase receptors (VEGFR-1, VEGFR-2, and VEGFR-3) and neuropilin receptors (NRP-1 and NRP-2), to promote angiogenesis and lymphangiogenesis. VEGF-A, the primary component of the VEGF family, binds to VEGFR-2 to stimulate… More >

Junqi Guo^1,2, Yun Yang^1,2, Wei Zhao^1,2, Zhonghai Yan³, Xia Yang⁴, Yunfei Yan^1,2, Ruimin Hao^1,2, Jinxia Hu^1,2,*, Fei Jiao^1,2,*

BIOCELL, Vol.49, No.9, pp. 1797-1797, 2025, DOI:10.32604/biocell.2025.071013 - 25 September 2025

Abstract This article has no abstract. More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.9, pp. 2599-2599, 2025, DOI:10.32604/or.2025.071884 - 28 August 2025

Abstract This article has no abstract. More >

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*

Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025

Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >

YUZHENG LI^1,2, LILI YU¹, SHIYAO ZHOU¹, HUA ZHOU^2,3,*, QIBIAO WU^1,2,*

Oncology Research, Vol.33, No.6, pp. 1363-1376, 2025, DOI:10.32604/or.2025.059311 - 29 May 2025

Abstract Background: Non-small cell lung cancer (NSCLC) involves complex alterations in the epidermal growth factor receptor (EGFR) signaling pathway. This study aims to integrate multimodal omics analyses to evaluate and enhance EGFR-targeted therapies. Methods: We reviewed and synthesized omics data—including genomics, transcriptomics, proteomics, epigenomics, and metabolomics data—related to the EGFR pathway in NSCLC, examined the clinical outcomes of current therapies and proposed new treatment strategies. Results: Integrated omics analyses revealed the multifaceted role of EGFR in NSCLC. Transcriptomic analysis revealed gene expression alterations due to EGFR mutations, with upregulation of oncogenes and downregulation of tumor suppressors. Proteomics More >

JIAHENG WEI¹, LIANGMING ZHU^2,*

Oncology Research, Vol.33, No.4, pp. 863-872, 2025, DOI:10.32604/or.2024.054201 - 19 March 2025

Abstract Lung cancer is one of the main causes of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) being the most prevalent histological subtype of lung cancer. Glutathione peroxidase 4 (GPX4) is a crucial antioxidant enzyme that plays a role in regulating ferroptosis. It is also involved in a wide variety of biological processes, such as tumor cell growth invasion, migration, and resistance to drugs. This study comprehensively examined the role of GPX4 in NSCLC and investigated the clinical feasibility of targeting GPX4 for NSCLC treatment. We discovered that GPX4 influences the progression of NSCLC More >

JIYUN PANG^1,2,#, WEIGANG XIU^1,#, YUEYUN CHEN⁴, WENJING LIAO^1,2, QIN ZHANG^3,*, HUASHAN SHI^4,*

Oncology Research, Vol.33, No.4, pp. 895-904, 2025, DOI:10.32604/or.2024.053363 - 19 March 2025

Abstract Background: Non-small cell lung cancer (NSCLC) is often accompanied by brain metastasis (BM), and the prognosis of patients with BM is poor. This study assesses the prognostic impact of BM in NSCLC patients with epidermal growth factor receptor (EGFR) mutations. Methods: We retrospectively evaluated 692 advanced NSCLC patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) at West China Hospital from 2015 to 2019. The overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), disease control rate (DCR), and clinical parameters of the BM and non-BM groups were compared. Univariable and multivariable… More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.3, pp. 733-733, 2025, DOI:10.32604/or.2024.056906 - 28 February 2025

Abstract This article has no abstract. More >